Microbiota long-term dynamics and prediction of acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.

Acute GvHD Amplicon sequence variants Antibiotics Gut, oral, and nasal microbiota HSCT Holobiont Immune reconstitution Machine learning Microbiome Prediction

Journal

Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147

Informations de publication

Date de publication:
28 06 2021
Historique:
received: 19 02 2021
accepted: 20 05 2021
entrez: 29 6 2021
pubmed: 30 6 2021
medline: 13 7 2021
Statut: epublish

Résumé

Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) exhibit changes in their gut microbiota and are experiencing a range of complications, including acute graft-versus-host disease (aGvHD). It is unknown if, when, and under which conditions a re-establishment of microbial and immunological homeostasis occurs. It is also unclear whether microbiota long-term dynamics occur at other body sites than the gut such as the mouth or nose. Moreover, it is not known whether the patients' microbiota prior to HSCT holds clues to whether the patient would suffer from severe complications subsequent to HSCT. Here, we take a holobiont perspective and performed an integrated host-microbiota analysis of the gut, oral, and nasal microbiota in 29 children undergoing allo-HSCT. The bacterial diversity decreased in the gut, nose, and mouth during the first month and reconstituted again 1-3 months after allo-HSCT. The microbial community composition traversed three phases over 1 year. Distinct taxa discriminated the microbiota temporally at all three body sides, including Enterococcus spp., Lactobacillus spp., and Blautia spp. in the gut. Of note, certain microbial taxa appeared already changed in the patients prior to allo-HSCT as compared with healthy children. Acute GvHD occurring after allo-HSCT could be predicted from the microbiota composition at all three body sites prior to HSCT. The reconstitution of CD4 This study reveals for the first time bacteria in the mouth and nose that may predict aGvHD. Monitoring of the microbiota at different body sites in HSCT patients and particularly through involvement of samples prior to transplantation may be of prognostic value and could assist in guiding personalized treatment strategies. The identification of distinct bacteria that have a potential to predict post-transplant aGvHD might provide opportunities for an improved preventive clinical management, including a modulation of microbiomes. The host-microbiota associations shared between several body sites might also support an implementation of more feasible oral and nasal swab sampling-based analyses. Altogether, the findings suggest that the microbiota and host factors together could provide actionable information to guiding precision medicine. Video Abstract.

Sections du résumé

BACKGROUND
Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) exhibit changes in their gut microbiota and are experiencing a range of complications, including acute graft-versus-host disease (aGvHD). It is unknown if, when, and under which conditions a re-establishment of microbial and immunological homeostasis occurs. It is also unclear whether microbiota long-term dynamics occur at other body sites than the gut such as the mouth or nose. Moreover, it is not known whether the patients' microbiota prior to HSCT holds clues to whether the patient would suffer from severe complications subsequent to HSCT. Here, we take a holobiont perspective and performed an integrated host-microbiota analysis of the gut, oral, and nasal microbiota in 29 children undergoing allo-HSCT.
RESULTS
The bacterial diversity decreased in the gut, nose, and mouth during the first month and reconstituted again 1-3 months after allo-HSCT. The microbial community composition traversed three phases over 1 year. Distinct taxa discriminated the microbiota temporally at all three body sides, including Enterococcus spp., Lactobacillus spp., and Blautia spp. in the gut. Of note, certain microbial taxa appeared already changed in the patients prior to allo-HSCT as compared with healthy children. Acute GvHD occurring after allo-HSCT could be predicted from the microbiota composition at all three body sites prior to HSCT. The reconstitution of CD4
CONCLUSIONS
This study reveals for the first time bacteria in the mouth and nose that may predict aGvHD. Monitoring of the microbiota at different body sites in HSCT patients and particularly through involvement of samples prior to transplantation may be of prognostic value and could assist in guiding personalized treatment strategies. The identification of distinct bacteria that have a potential to predict post-transplant aGvHD might provide opportunities for an improved preventive clinical management, including a modulation of microbiomes. The host-microbiota associations shared between several body sites might also support an implementation of more feasible oral and nasal swab sampling-based analyses. Altogether, the findings suggest that the microbiota and host factors together could provide actionable information to guiding precision medicine. Video Abstract.

Identifiants

pubmed: 34183060
doi: 10.1186/s40168-021-01100-2
pii: 10.1186/s40168-021-01100-2
pmc: PMC8240369
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

148

Subventions

Organisme : Horizon2020
ID : 643476

Références

Nucleic Acids Res. 2013 Jan 7;41(1):e1
pubmed: 22933715
Microbiome. 2019 Sep 13;7(1):131
pubmed: 31519210
J Oral Pathol Med. 2012 Aug;41(7):568-76
pubmed: 23019688
Support Care Cancer. 2011 Jul;19(7):995-1000
pubmed: 20535502
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Genome Biol. 2014;15(12):550
pubmed: 25516281
Immunology. 2017 Aug;151(4):363-374
pubmed: 28542929
mSystems. 2016 Oct 18;1(5):
pubmed: 27822556
Clin Infect Dis. 2012 Oct;55(7):905-14
pubmed: 22718773
Biol Blood Marrow Transplant. 2017 May;23(5):845-852
pubmed: 28232086
Clin Infect Dis. 2019 Apr 8;68(8):1303-1310
pubmed: 30124813
Transplant Proc. 2017 Nov;49(9):2176-2182
pubmed: 29149979
Biol Blood Marrow Transplant. 2014 May;20(5):640-5
pubmed: 24492144
Bioinformatics. 2011 Feb 15;27(4):592-3
pubmed: 21169378
PLoS Comput Biol. 2014 Apr 03;10(4):e1003531
pubmed: 24699258
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643233
F1000Res. 2016 Jun 24;5:1492
pubmed: 27508062
Immunobiology. 2018 Feb;223(2):220-226
pubmed: 29033080
Int J Food Microbiol. 2019 Mar 2;292:72-82
pubmed: 30579059
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
PLoS Comput Biol. 2017 Aug 18;13(8):e1005706
pubmed: 28821012
Blood. 2014 Aug 14;124(7):1174-82
pubmed: 24939656
Bone Marrow Transplant. 2015 Jul;50(7):992-8
pubmed: 25893458
Nature. 2016 Jul 06;535(7610):75-84
pubmed: 27383982
Biol Blood Marrow Transplant. 2015 Aug;21(8):1373-83
pubmed: 25977230
Int J Cancer. 2020 Oct 1;147(7):1953-1962
pubmed: 32115690
Free Radic Biol Med. 2017 Apr;105:93-101
pubmed: 27677568
Risk Anal. 2019 Jun;39(6):1397-1413
pubmed: 30462833
Microbiome. 2018 Dec 17;6(1):226
pubmed: 30558668
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
Nature. 2013 Aug 8;500(7461):232-6
pubmed: 23842501
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Nat Rev Cancer. 2018 May;18(5):283-295
pubmed: 29449660
N Engl J Med. 2020 Feb 27;382(9):822-834
pubmed: 32101664
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Cell Host Microbe. 2016 Aug 10;20(2):202-14
pubmed: 27476413
Front Immunol. 2018 Apr 24;9:669
pubmed: 29740427
Cell. 2012 Jun 22;149(7):1578-93
pubmed: 22726443
Blood. 2010 Aug 19;116(7):1165-71
pubmed: 20484086
Open Forum Infect Dis. 2017 Oct 06;4(4):ofx215
pubmed: 29226172
Am J Transplant. 2020 Apr;20(4):1014-1027
pubmed: 31605563
PLoS Comput Biol. 2017 Feb 21;13(2):e1005404
pubmed: 28222096
Transplantation. 1974 Oct;18(4):295-304
pubmed: 4153799
Biol Blood Marrow Transplant. 2018 Jul;24(7):1322-1340
pubmed: 29471034
Bone Marrow Transplant. 2017 Dec;52(12):1643-1650
pubmed: 28967895
Sci Transl Med. 2016 May 18;8(339):339ra71
pubmed: 27194729
J Exp Med. 2012 May 7;209(5):903-11
pubmed: 22547653
Science. 2019 Nov 29;366(6469):1143-1149
pubmed: 31780560
Blood. 2015 Oct 1;126(14):1723-8
pubmed: 26209659
Nat Immunol. 2016 May;17(5):505-513
pubmed: 26998764
Arch Microbiol. 2018 May;200(4):525-540
pubmed: 29572583
Clin Infect Dis. 2017 Nov 29;65(12):1984-1991
pubmed: 29020185
Front Immunol. 2017 Mar 20;8:79
pubmed: 28373870

Auteurs

Anna Cäcilia Ingham (AC)

Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark.
Present address: Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.

Katrine Kielsen (K)

Institute for Inflammation Research, Department of Rheumatology and Spine Disease, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Hanne Mordhorst (H)

Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark.

Marianne Ifversen (M)

Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Frank M Aarestrup (FM)

Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark.

Klaus Gottlob Müller (KG)

Institute for Inflammation Research, Department of Rheumatology and Spine Disease, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Sünje Johanna Pamp (SJ)

Research Group for Genomic Epidemiology, Technical University of Denmark, Kongens Lyngby, Denmark. sjpa@dtu.dk.
Present address: Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kongens Lyngby, Denmark. sjpa@dtu.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH